Nullane salus extra ecclesiam
Randomized clinical trials are not relevant for infectious disease outbreaks due to a new pathogen, for which public health decisions have to be made urgently. An approach based on group comparisons, in silico, may provide valuable results in a reasonably short period of time for a negligible amount...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-09-01
|
| Series: | New Microbes and New Infections |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2052297520300664 |
| _version_ | 1828467820405456896 |
|---|---|
| author | P. Gautret D. Raoult |
| author_facet | P. Gautret D. Raoult |
| author_sort | P. Gautret |
| collection | DOAJ |
| description | Randomized clinical trials are not relevant for infectious disease outbreaks due to a new pathogen, for which public health decisions have to be made urgently. An approach based on group comparisons, in silico, may provide valuable results in a reasonably short period of time for a negligible amount of money. |
| first_indexed | 2024-12-11T04:12:44Z |
| format | Article |
| id | doaj.art-c8041f53ea9b4954953c47a24c97cd70 |
| institution | Directory Open Access Journal |
| issn | 2052-2975 |
| language | English |
| last_indexed | 2024-12-11T04:12:44Z |
| publishDate | 2020-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | New Microbes and New Infections |
| spelling | doaj.art-c8041f53ea9b4954953c47a24c97cd702022-12-22T01:21:20ZengElsevierNew Microbes and New Infections2052-29752020-09-0137100714Nullane salus extra ecclesiamP. Gautret0D. Raoult1IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Corresponding author: P. Gautret, IHU—Méditerranée Infection, 19–21 boulevard Jean Moulin, 13005, Marseille, France.IHU-Méditerranée Infection, Marseille, France; Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, FranceRandomized clinical trials are not relevant for infectious disease outbreaks due to a new pathogen, for which public health decisions have to be made urgently. An approach based on group comparisons, in silico, may provide valuable results in a reasonably short period of time for a negligible amount of money.http://www.sciencedirect.com/science/article/pii/S2052297520300664Chloroquine derivativesclinical trialsCOVID-19in silico comparisonSARS-CoV-2 |
| spellingShingle | P. Gautret D. Raoult Nullane salus extra ecclesiam New Microbes and New Infections Chloroquine derivatives clinical trials COVID-19 in silico comparison SARS-CoV-2 |
| title | Nullane salus extra ecclesiam |
| title_full | Nullane salus extra ecclesiam |
| title_fullStr | Nullane salus extra ecclesiam |
| title_full_unstemmed | Nullane salus extra ecclesiam |
| title_short | Nullane salus extra ecclesiam |
| title_sort | nullane salus extra ecclesiam |
| topic | Chloroquine derivatives clinical trials COVID-19 in silico comparison SARS-CoV-2 |
| url | http://www.sciencedirect.com/science/article/pii/S2052297520300664 |
| work_keys_str_mv | AT pgautret nullanesalusextraecclesiam AT draoult nullanesalusextraecclesiam |